Inovio Pharmaceuticals (INO) Assets Average (2011 - 2026)
Inovio Pharmaceuticals (INO) posted Assets Average of $62.0 million for Q1 2026, down 13.65% sequentially from $71.8 million in Q4 2025, and down 38.1% YoY from $100.2 million in Q1 2025.
Inovio Pharmaceuticals (INO) Assets Average (2011 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Assets Average for 16 years, with the latest figure at $62.0 million in Q1 2026.
- Quarterly Assets Average fell 38.1% year-over-year to $62.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.0 million (down 38.1% YoY) and the FY2025 annual result came in at $93.8 million, down 34.01% from the prior year.
- Assets Average slipped to $62.0 million in Q1 2026 per INO's latest filing, from $71.8 million in the prior quarter.
- Over five years, Assets Average peaked at $470.7 million in Q1 2022 and troughed at $62.0 million in Q1 2026.
- A 5-year average of $209.7 million and a median of $150.0 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2024: Assets Average decreased 21.19% in 2022, then sank 51.22% in 2024.
- Over 5 years, Assets Average stood at $370.3 million in 2022, then sank by 50.84% to $182.0 million in 2023, then plunged by 39.5% to $110.1 million in 2024, then tumbled by 34.76% to $71.8 million in 2025, then decreased by 13.65% to $62.0 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $62.0 million, $71.8 million, and $68.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Inovio Pharmaceuticals | 97.94 Mn | 97.94 Mn | - | 49.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.58 Mn |
| Mar 31, 2026 | 62.04 Mn |
| Dec 31, 2025 | 71.85 Mn |
| Sep 30, 2025 | 68.81 Mn |
| Jun 30, 2025 | 77.76 Mn |
| Mar 31, 2025 | 100.23 Mn |
| Dec 31, 2024 | 110.13 Mn |
| Sep 30, 2024 | 120.43 Mn |
| Jun 30, 2024 | 131.46 Mn |
| Mar 31, 2024 | 150.03 Mn |
| Dec 31, 2023 | 182.02 Mn |
| Sep 30, 2023 | 213.07 Mn |
| Jun 30, 2023 | 249.81 Mn |
| Mar 31, 2023 | 307.56 Mn |
| Dec 31, 2022 | 370.25 Mn |
| Sep 30, 2022 | 425.68 Mn |
| Jun 30, 2022 | 452.46 Mn |
| Mar 31, 2022 | 470.73 Mn |
| Dec 31, 2021 | 515.85 Mn |
| Sep 30, 2021 | 563.80 Mn |